DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Robson ME, Tung N, Conte P. et al
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Ann Oncol 2019;
30: 558-566 . doi:10.1093/annonc/mdz012
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.